Polymorphisms in CYP2C9, a critical cytochrome P-450 enzyme in the metabolism of
warfarin, alters its clearance and affects dosing. CYP* 1 has higher activity than either the* 2 …

Three factor Xa inhibitors have been studied in the treatment of venous thromboembolism,
both for acute therapy and as extended therapy to prevent recurrent events. Rivaroxaban …

Essentials• In this crossover study the anticoagulant effects of rivaroxaban and apixaban
were compared.• Healthy volunteers received rivaroxaban 20 mg once daily or apixaban 5 …

Following major orthopaedic surgery, guidelines usually recommend continued
thromboprophylaxis after hospitalisation. The availability of an effective oral anticoagulant …

Venous thromboembolic disease, including deep vein thrombosis and pulmonary embolism,
is a cause of significant mortality and morbidity. For several decades, anticoagulant options …

Background A substantial portion of patients with atrial fibrillation (AF) also have coronary
artery disease (CAD) and are at risk for coronary events. Warfarin is known to reduce these …

Background: Guidelines recommend warfarin as the standard of care for patients with atrial
fibrillation (AF) at moderate or high risk for stroke. This phase II study assessed the effects of …

Background: Although not routinely recommended, anti-Xa level monitoring for apixaban or
rivaroxaban may be useful in certain clinical scenarios. There are currently no laboratory …

Background: Apixaban is an oral, potent, highly selective, reversible and direct inhibitor of
activated coagulation factor X, that is the end point of the intrinsic and extrinsic coagulation …

Apixaban, an inhibitor of direct factor Xa, is used for the treatment of venous thromboembolic
events or prevention of stroke. Unlike many other anticoagulant agents, it does not need …